SCHEMBL1933778

SCHEMBL1933778

Oc1ccc2c(c1)OC(c1ccccc1)CC2O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 8/20 0.60
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54
PSMB5 P28074 1/20 0.54
AR P10275 1/20 0.50
CYP1A1 P04798 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP1B1 Q16678 1/20 0.45
MEN1 O00255 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ESR2 Q92731 2/20 0.44
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
YES1 P07947 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7048656 1.00 CYP19A1 (0.60) CYP19A1MAOAMAOBPSMB5AR
SCHEMBL4365834 0.88 AR (0.54) CYP19A1MAOAMAOBPSMB5AR
SCHEMBL5744717 0.84 AR (0.52) CYP19A1MAOAMAOBPSMB5AR
SCHEMBL1933397 0.84 CYP19A1 (0.44) CYP19A1MAOAMAOBARMEN1
SCHEMBL10365101 0.83 CYP19A1 (0.53) CYP19A1MAOAMAOBPSMB5AR
SCHEMBL30064231 0.82 CYP19A1 (0.45) CYP19A1MAOAMAOBPSMB5AR
SCHEMBL1267388 0.82 CYP19A1 (0.45) CYP19A1MAOAMAOBPSMB5AR
SCHEMBL380283 0.82 CYP19A1 (0.45) CYP19A1MAOAMAOBPSMB5AR
SCHEMBL25567835 0.81 CYP3A4 (0.50) CYP19A1MAOAMAOBPSMB5AR
SCHEMBL4367671 0.81 ESR1 (0.51) CYP19A1ARCYP3A4ESR2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289501-A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls NOVARTIS AG (CH) 2012-11-15 US disclosed
EP-2504339-A1 BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS Novartis AG (CH) 2012-10-03 EP disclosed
EP-2484773-A2 Process for producing anthocyanins The Research Foundation of State University of New York (US) 2012-08-08 EP disclosed
WO-2011064211-A1 BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS NOVARTIS AG (CH) 2011-06-03 WO disclosed
US-7807422-B2 set of genes which encodes for enzymes which can convert substrates belonging to the general category of phenylpropanoids and result in the production of flavanones; without the need for chemical conversion THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2010-10-05 US disclosed
US-20090239272-A1 set of genes which encodes for enzymes which can convert substrates belonging to the general category of phenylpropanoids and result in the production of flavanones; without the need for chemical conversion KOFFAS MATTHEOS 2009-09-24 US disclosed
US-7338791-B2 Introducing the set of genes into a heterologous host cell, allowing growth of the cells in a suitable medium such that the expression of the genes results in production of enzymes; culturing the cell under conditions permitting the synthesis of the flavonoid by the cells; isolating s flavonoids THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2008-03-04 US disclosed
US-20060019334-A1 Introducing the set of genes into a heterologous host cell, allowing growth of the cells in a suitable medium such that the expression of the genes results in production of enzymes; culturing the cell under conditions permitting the synthesis of the flavonoid by the cells; isolating s flavonoids NATIONAL SCIENCE FOUNDATION 2006-01-26 US disclosed
US-4105675-A REDUCING ACYLATED FLAVANONE WITH ALKALI BOROHYDRIDE TO REMOVE OXYGEN FUNCTION AT 4-POSITION; OXIDIZING WITH HALOGENATED BENZOQUINONE TO FORM SALT THE COCA-COLA COMPANY (US) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289501-A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls CYP1B1, CYP11B2, CCNI CYP19A1 51/4885MAOA 576/4885MAOB 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.